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Atrial Enlargement as a Consequence of Atrial Fibrillation
Sanfilippo et all report that atrial enlargement can develop as a consequence of atrial fibrillation. This conclusion is based upon the determination by echocardiography of atrial volumes in a highly selected group of 15 patients without any 'confounding cause for atrial enlargement." Atrial dimensions were measured in various projections and volume calculated on the assumption that the atria were prolate ellipses. For the right atriunm, two of the dimensions employed to determine volume were regarded as equivalent! The problems inherent in these measurements and assumptions were described in a study reported in this journal long ago2 in which no relationship was found between left atrial volume as determined by angiocardiography and duration of atrial fibrillation.
Sanfilippo et al' use their findings to support more aggressive attempts to eliminate atrial fibrillation. Yet in this "perfect" group of 15 patients with atrial fibrillation, electrical conversion failed in five, chemical conversion failed in an additional four, and no attempt at conversion was made in the remaining six and no reasons were given for not trying. Finally, endpoints3 for digoxin dosage are not mentioned in the 11 who were maintained on digoxin, or for control of the ventricular rate in the other four who were not.
Atrial fibrillation is an unwanted arrhythmia, but its abolition to prevent atrial enlargement remains unproved. It is at once thought-provoking and sobering to learn from the work of Sanfilippo et all that restitution of sinus rhythm in these ideal patients was unsuccessful in every instance in which cardioversion was attempted, whether electrically or chemically. Jacob Our study group' was selected from a large registry of patients with atrial fibrillation. The selection criteria, as laid out in the paper, were designed to exclude patients with preexisting structural cardiac abnormalities that could potentially cause chamber enlargement and therefore confound our results. This resulted in a study group that comprised only a minority of the patients in the registry. This reflects the well-established clinical observation that in the majority of cases atrial fibrillation is associated with morphological abnormalities or has already resulted in chamber enlargement by the time it is clinically detected. Although only 15 patients qualified and were able to complete the study, this group was large enough to demonstrate statistical significance.
The calculation of atrial volume from dimensions determined in multiple imaging planes does require geometric assumptions regarding chamber shape that can be criticized. However, we would point out that all five measured atrial dimensions were shown to individually increase significantly. Even without geometric assumptions as to atrial shape, therefore, the progression in chamber size is established.
The clinical management of these patients prior to their entry in this study was determined entirely by the individual attending physicians. As Dr. Zatuchni points out, there was considerable variation in approach. However, no attempts at cardioversion were undertaken during the study. Because there would appear to be no a priori reason that previous medical or electrical management should continuously affect chamber size, the variations in approach should not detract from the conclusions. The marked variability in clinical approach emphasizes the lack of information in this area and adds to the relevance of these observations.
Finally, our paper points out that atrial fibrillation can lead to atrial enlargement in patients without preexisting morphologic or structural abnormalities. We agree that the premise that abolition of atrial fibrillation prevents such enlargement remains unproven. However, we feel that our work raises this possibility, which has clear implications for management of these patients and should be addressed in further prospective studies.
Anthony J. Sanfilippo 
Treatment ofAcute or Recurrent Pericarditis With Colchicine
We read with interest the study of Dr. Guindo and colleagues' on the treatment of recurrent pericarditis with colchicine. After their initial publication concerning three cases,2 we began, in June 1988, an open study to confirm their findings on a larger series of patients. Colchicine was prescribed not only to prevent recurrences in cases of recurrent pericarditis but also in cases of a first episode of pericarditis, to cure the acute phase and to avoid further recurrences. Indeed, in cases of a first episode of pericarditis, further recurrences can occur in 30% of patients, sometimes during the first month after the initial episode. 3 We thus hoped to prevent recurrences by prescribing colchicine in every patient as early as the inaugural episode of pericarditis.
The therapeutic protocol we used was slightly different: colchicine was prescribed at a loading dose of 3 mg the first day, after total interruption of previous anti-inflammatory drugs. During the next 2 days, 2 mg daily was given. The maintenance dose was 1 mg
